CONSTIMOD: Efficacy of Sacral Nerve Modulation in Severe Refractory Constipation

Sponsor
University Hospital, Bordeaux (Other)
Overall Status
Completed
CT.gov ID
NCT01629303
Collaborator
(none)
20
11
2
31
1.8
0.1

Study Details

Study Description

Brief Summary

Subjects with refractory chronic constipation are offered two conventional therapeutic strategies: either medical treatment, either surgery (in the case of medication failure). Nevertheless, a procedure less invasive than surgery could be an alternative strategy: the sacral nerve modulation. This procedure consists in stimulating the nerves which control the contractions of the colon and so the defecation phenomenon. Several open trials have suggested that sacral nerve modulation may be effective in reducing constipation and related symptoms. The aim of this randomized clinical trial is to assess the efficacy of the sacral nerve stimulation in patients with constipation.

Condition or Disease Intervention/Treatment Phase
  • Procedure: sacral nerve modulation
Phase 2

Detailed Description

The prevalence of constipation is 2-27% in Western countries. For patients failing medical treatment (laxatives, biofeedback), a surgical solution may be considered (subtotal colectomy). But results are variable and it puts them at risk of functional sequelae.

Sacral nerve modulation is a minimally invasive procedure compared with the standard surgical support (colectomy) and reversible, which consists in two stages. First, a 3-week temporary stimulation test allows verifying the efficacy of neuromodulation. If the test is positive, the stimulating electrode is definitely implanted. Risks related to the procedure (infection, pain) are much smaller than those associated with a conventional surgical support.

Non comparative studies conducted with 19 and 62 patients showed that 40-73% of implanted patients have an improvement of their constipation and could benefit of permanent implantation with good results in medium term.

The primary objective of the investigators study is to evaluate the short-term efficacy (percentage of responders at 2 months) of sacral nerve modulation in the treatment of severe chronic constipation.

This is a cross-over designed, double-blinded, French multicenter clinical trial, including two periods: 2 months of stimulation ON and 2 months of stimulation OFF. Between these two periods, a 15-days period of "wash-out" will be respected during which all patients will be in OFF mode (4.5 months in total). This period of 4.5 months will be extended by a follow-up period of 7 months during which all patients will be treated (stimulation ON).

If this trial showed efficiency of this procedure, patients with severe refractory constipation could benefit of a sacral nerve modulation test before considering a surgical treatment.

Study Design

Study Type:
Interventional
Actual Enrollment :
20 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Efficacy of Sacral Nerve Modulation in Severe Refractory Constipation
Study Start Date :
Jun 1, 2012
Actual Primary Completion Date :
Nov 1, 2013
Actual Study Completion Date :
Jan 1, 2015

Arms and Interventions

Arm Intervention/Treatment
Experimental: Arm on-off

After the definitive implantation, stimulators are placed in position OFF during 8 weeks. Then all the stimulators are switched OFF for 15 days. Finally stimulators are switched ON for the second arm during 8 weeks

Procedure: sacral nerve modulation
After the definitive implantation, stimulators are placed in position ON (arm on-off) or OFF (arm off-on) for the first arm and in position OFF for the second arm during 8 weeks. Then all the stimulators are switched OFF (both first and second arms) for 15 days. Finally stimulators are maintained in position OFF for the first arm and switched ON for the second arm during 8 weeks

Experimental: Arm off-on

After the definitive implantation, stimulators are placed in position ON during 8 weeks. Then all the stimulators are switched OFF for 15 days. Finally stimulators are maintained in position OFF during 8 weeks

Procedure: sacral nerve modulation
After the definitive implantation, stimulators are placed in position ON (arm on-off) or OFF (arm off-on) for the first arm and in position OFF for the second arm during 8 weeks. Then all the stimulators are switched OFF (both first and second arms) for 15 days. Finally stimulators are maintained in position OFF for the first arm and switched ON for the second arm during 8 weeks

Outcome Measures

Primary Outcome Measures

  1. Percentage of patients showing a positive response to sacral nerve stimulation at 2 months [2 months of the stimualtion period]

    Percentage of patients showing a positive response to sacral nerve stimulation during the period " ON " compared with the period " OFF " based on an objective assessment of the number of feces and their characteristics

Secondary Outcome Measures

  1. Clinical characteristics, manometry data, Wexner score of responders to stimulation during the temporary stimulation test (period before the permanent implantation) [3 weeks between temporary and permanent implantations]

  2. Clinical characteristics, manometry data, Wexner score of responders to short-term stimulation [2 months after permanent implantation]

  3. Efficacy of neuromodulation [1 year after permanent implantation]

    Efficacy of neuromodulation (percentage of positive responders) at 1 year

  4. Manometry data, Wexner, QoL and EVA scores, time of colonic transit of responders to prolonged stimulation [1 year after permanent implantation]

  5. To evaluate the investigator opinion about the neuromodulation response, using the patient diary. [1 year after permanent implantation]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age ≥ 18 years old

  • Constipation defined by at least two of the following criteria :

  • Frequency of 2 stools or less per week

  • Severe outlet constipation, i.e. need to use digital extraction or enemas more than 25% of time

  • Sensation of incomplete evacuation more than 25% of time

  • Refractory constipation since at least 1 year to medical treatment (drug treatment and/or biofeedback) conducted in the centre (failure or intolerance to laxative osmotic treatments, stimulants, and prucalopride) for which surgery is discussed

  • Patients supported in the centre for at least 3 months before inclusion

  • Patients having social security system

  • Patients having read and signed informed consent form

Exclusion Criteria:
  • Constipation secondary to ano-rectal malformation, surgical sequel, colorectal or anal organic lesions, or pelvi-perineal static disorder indicated for surgical treatment

  • Constipation secondary to neurological pathology and/or concomitant treatments intake (opiates, anticholinergic agents)

  • Partial colectomy history

  • Patients in whom implantation of stimulating electrode is impossible due to anatomical reasons (e.g. sacral agenesis)

  • Pregnant female patients or with childbearing potential without adequate contraceptive barrier (oestrogen-progesterone contraceptives or intra-uterine device)

  • Skin disease associated with a risk of infection - in the opinion of the investigator

  • Patient with pacemaker or defibrillator

  • Patient exposed to resonance magnetic imaging

  • Psychiatric disease incompatible with use of the treatment - in the opinion of the investigator

  • Patient misunderstanding oral and written French language

  • Patient participating to another study

  • Patients who don't complete the first diary without missing data (concerning items used to define the primary endpoint)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Service d' Hépato-gastro-entérologie CHU de Limoges Limoges France 87000
2 Service d'hépato-gastroentérologie et oncologie digestive Bordeaux France 33075
3 Service d'hépato-gastroentérologie - CHU estaing Clermont Ferrand France 63000
4 Service de gastroentérologie - AP HP Colombes France 92000
5 Service de Chirurgie générale - CHU de Grenoble Grenoble France 38000
6 Service d'exploration fonctionnelle digestive -Hospices Civils de Lyon Lyon France 69000
7 Service de gastroentérologie - hopital nord -AP-HM Marseille France 13000
8 : Clinique de chirurgie digestive et endocrinienne. Institut des Maladies de l'Appareil Digestif (IMAD Nantes France 44000
9 SMAD CHU Pontchaillou -Rennes Rennes France 35000
10 Service de physiologie digestive, urinaire, respiratoire et sportive - CHU de rouen Rouen France 76000
11 Service d'hépato-gastroentérologie et explorations fonctionnelles digestives - CHU de Tours Tours France 37000

Sponsors and Collaborators

  • University Hospital, Bordeaux

Investigators

  • Principal Investigator: Frank ZERBIB, Professor, University Hospital, Bordeaux
  • Study Chair: Genevieve CHENE, Professor, University Hospital, Bordeaux

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Hospital, Bordeaux
ClinicalTrials.gov Identifier:
NCT01629303
Other Study ID Numbers:
  • CHUBX 2011/23
First Posted:
Jun 27, 2012
Last Update Posted:
Jul 23, 2015
Last Verified:
Jul 1, 2015
Keywords provided by University Hospital, Bordeaux
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 23, 2015